Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 16
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
AstraZeneca PLC
AZN
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$166.68
4.65
2.87%
Ult. Agg.: Oct 16, 5:03 AM
$166.69
4.66
2.88%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 14 giorni da adesso in ven ott 30th, prima dell'apertura del mercato
AstraZeneca Financials
AstraZeneca (AZN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.
Vandana Singh
Dow Gains Over 250 Points Amid Lower Oil Prices: Investor Sentiment Weakens, Greed Index Remains In ‘Fear’ Zone
U.S. stocks mixed as Dow gains 250 points amid decline in oil prices. CNN Money Fear and Greed Index shows market sentiment in Fear zone.
Avi Kapoor
Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition
AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sales up 16%. Get the full recap.
Vandana Singh
PRO
AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates
Benzinga Newsdesk
PRO
AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate
AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.48 by 6.05 percent. This is a 141.28 percent increase over earnings of $1.08 per share from the
Benzinga Newsdesk
Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
Lekha Gupta
